search for




 

Impulse Control Disorders associated with Pramipexole/Ropinirole Use in Non-Parkinson’s Disease: A Scoping Review
Korean J Clin Pharm 2020;30(4):250-258
Published online December 31, 2020
© 2020 Korean College of Clinical Pharmacy.

Tae hyun Jeong1†, Seoung Min Suh1†, Hyun Jin Song2, and Nakyung Jeon1 *

1Chonnam National University College of Pharmacy, Gwangju 61186, Republic of Korea
2University of Florida College of Pharmacy Department of Pharmaceutical Outcomes and Policy, Gainesveill, Florida 32610, United States of America
Correspondence to: Nakyung Jeon, Chonnam National University College of Pharmacy, College of Pharmacy Building #1-407, Yongbongro 77, Buk-gu, Gwangju 61186, Republic of Korea
Tel: +82-62-530-2929
E-mail: nakyung.jeon@jnu.ac.kr

These authors contributed equally to this work qualifying as the first authors.
Received October 24, 2020; Revised December 7, 2020; Accepted December 10, 2020.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background: Dopamine receptor agonists (DRAs) have been associated with impulse control disorders (ICDs) in Parkinson’s disease (PD) in preliminary studies. Whether the association holds true when DRAs are used to treat non-PD, such as restless legs syndrome, prolactinoma, and several mood disorders is uncertain.
Objective: The present study aimed to understand the research gaps related to the risk of ICDs associated with pramipexole or ropinirole (PRX/ROP) use as a treatment for specific underlying diseases, excluding Parkinson’s disorders.
Methods: We conducted a scoping review, systematically searching databases to identify literature on the types, prevalence, and factors associated with ICD in non-PD patients receiving PRX/ROP. All relevant information that helped understand the epidemiology of ICDs among non-PD patients taking PRX/ROP were extracted and analyzed. We also evaluated the potential associations between PRX/ROP and ICDs, utilizing the Naranjo scale or statistical analysis, depending on the type of literature.
Results: We included 24 articles (19 case reports or case series and 5 populationbased studies) in this scoping review. Evaluating the 19 case reports or case series using Naranjo scores led to the discovery of a possible link between PRX/ROP exposure and ICDs. However, important information to assess causality is frequently missing. Moreover, the population-based studies lack diversity in the study populations and enough study samples to draw conclusive results.
Conclusion: Our scoping review suggests that the currently available literature requires more details in future case reports and for well-powered studies in various disease conditions where PRX/ROP is frequently used.
Keywords : Scoping review, impulse control disorder, restless legs syndrome, pramipexole, ropinirole


December 2020, 30 (4)
Full Text(PDF) Free

Social Network Service
Services

Cited By Articles
  • CrossRef (0)